A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

计划入组 134 人 · 首次发布于 2016 年 8 月 5 日

Clinical Studies of Progeria

计划入组 15 人 · 首次发布于 2004 年 10 月 18 日

Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery

计划入组 465 人 · 首次发布于 2019 年 1 月 8 日

IDO1 inhibitors(Hutchison MediPharma)

HMPL-004

Liraglutide biosimilar(Biocon Limited)

Shanghai Hutchison Pharmaceuticals Limited

China

MEDIPHARMA

Tunisia

IMUGENE LIMITED

Australia

Advancements in HER2-Positive Gastric Cancer Treatment Landscape

Hutchison MediPharma's Sovleplenib Demonstrates Efficacy in Autoimmune Disorders

Neuroendocrine Tumor Pipeline Shows Strong Growth with 75+ Therapies in Development